<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One mechanism for disrupting the MLL gene in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is through partial tandem duplication (MLL-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e>); however, the mechanism by which MLL-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e> contributes to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> development and maintenance is currently unknown </plain></SENT>
<SENT sid="1" pm="."><plain>Herein, we investigated hematopoietic stem/progenitor cell (HSPC) phenotypes of Mll-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e> knock-in mice </plain></SENT>
<SENT sid="2" pm="."><plain>Although HSPCs (Lin(-)Sca1(+)Kit(+) (LSK)/SLAM(+) and LSK) in Mll(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e>/WT) mice are reduced in absolute number in steady state because of <z:mp ids='MP_0006042'>increased apoptosis</z:mp>, they have a proliferative advantage in colony replating assays, CFU-spleen assays, and competitive transplantation assays over <z:mp ids='MP_0002169'>wild-type</z:mp> HSPCs </plain></SENT>
<SENT sid="3" pm="."><plain>The Mll(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e>/WT)-derived phenotypic short-term (ST)-<z:chebi fb="15" ids="50443">HSCs</z:chebi>/multipotent progenitors and granulocyte/macrophage progenitors have self-renewal capability, rescuing hematopoiesis by giving rise to long-term repopulating cells in recipient mice with an unexpected myeloid differentiation blockade and lymphoid-lineage bias </plain></SENT>
<SENT sid="4" pm="."><plain>However, Mll(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e>/WT) HSPCs never develop <z:hpo ids='HP_0001909'>leukemia</z:hpo> in primary or recipient mice, suggesting that additional genetic and/or epigenetic defects are necessary for full leukemogenic transformation </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, the Mll-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e> aberrantly alters HSPCs, enhances self-renewal, causes lineage bias, and blocks myeloid differentiation </plain></SENT>
<SENT sid="6" pm="."><plain>These findings provide a framework by which we can ascertain the underlying pathogenic role of MLL-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTD</z:e> in the <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> of human <z:hpo ids='HP_0001909'>leukemia</z:hpo>, which should facilitate improved therapies and patient outcomes </plain></SENT>
</text></document>